• 1
    Bianchi C,Bianchi T. Malignant mesothelioma: global incidence and relationship with asbestos. Ind Health. 2007; 45: 379387.
  • 2
    Vogelzang NJ,Rusthoven JJ,Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003; 21: 26362644.
  • 3
    Kindler HL,Millard F,Herndon JEII. Gemcitabine for malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B. Lung Cancer. 2001; 31: 311317.
  • 4
    Mikulski SM,Costanzi JJ,Vogelzang NJ, et al. Phase II trial of a single weekly intravenous dose of ranpirnase in patients with unresectable malignant mesothelioma. J Clin Oncol. 2002; 20: 274–;281.
  • 5
    Sahmoud T,Postmus PE,van Pottelsberghe C, et al. Etoposide in malignant pleural mesothelioma: 2 phase II trials of the EORTC Lung Cancer Cooperative Group. Eur J Cancer. 1997; 33: 22112215.
  • 6
    Steele JP,Shamash J,Evans MT,Gower NH,Tischkowitz MD,Rudd RM. Phase II study of vinorelbine in patients with malignant pleural mesothelioma. J Clin Oncol. 2000; 18: 39123917.
  • 7
    van Meerbeeck JP,Baas P,Debruyne C, et al. A phase 2 study of gemcitabine in patients with malignant pleural mesothelioma. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. Cancer. 1999; 85: 25772582.
  • 8
    Lerner HJ,Schoenfeld DA,Martin A,Falkson G,Borden E. Malignant mesothelioma. The Eastern Cooperative Oncology Group (ECOG) experience. Cancer. 1983; 52: 19811985.
  • 9
    Manegold C,Symanowski J,Gatzemeier U, et al. Second-line (poststudy) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma. Ann Oncol. 2005; 16: 923927.
  • 10
    Konig J,Tolnay E,Wiethege T,Muller K. Co-expression of vascular endothelial growth factor and its receptor flt-1 in malignant pleural mesothelioma. Respiration. 2000; 67: 3640.
  • 11
    Konig JE,Tolnay E,Wiethege T,Muller KM. Expression of vascular endothelial growth factor in diffuse malignant pleural mesothelioma. Virchows Arch. 1999; 435: 812.
  • 12
    Strizzi L,Catalano A,Vianale G, et al. Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma. J Pathol. 2001; 193: 468475.
  • 13
    Dazzi H,Hasleton PS,Thatcher N,Wilkes S,Swindell R,Chatterjee AK. Malignant pleural mesothelioma and epidermal growth factor receptor (EGF-R). Relationship of EGF-R with histology and survival using fixed paraffin embedded tissue and the F4, monoclonal antibody. Br J Cancer. 1990; 61: 924926.
  • 14
    Govindan R,Suppiah R,Ritter J. EGFR and HER-2 overexpression in malignant mesothelioma [abstract]. Proc Am Soc Clin Oncol. 2001; 20: 3106.
  • 15
    Govindan R,Kratzke RA,Herndon JEII, et al. Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B. Clin Cancer Res. 2005; 11: 23002304.
  • 16
    Janne PA,Taffaro ML,Salgia R,Johnson BE. Inhibition of epidermal growth factor receptor signaling in malignant pleural mesothelioma. Cancer Res. 2002; 62: 52425247.
  • 17
    Hurwitz H,Fehrenbacher L,Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004; 350: 23352342.
  • 18
    Sandler A,Gray R,Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006; 355: 25422550.
  • 19
    Shepherd FA,Rodrigues Pereira J,Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005; 353: 123132.
  • 20
    Moore MJ,Goldstein D,Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. JClin Oncol. 2007; 25: 19601966.
  • 21
    Hainsworth JD,Sosman JA,Spigel DR,Edwards DL,Baughman C,Greco A. Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib. JClin Oncol. 2005; 23: 78897896.
  • 22
    Herbst RS,Johnson DH,Mininberg E, et al. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J Clin Oncol. 2005; 23: 25442555.
  • 23
    Oken MM,Creech RH,Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982; 5: 649655.
  • 24
    Byrne MJ,Nowak AK. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol. 2004; 15: 257260.
  • 25
    Simon R. Optimal 2-stage designs for phase II clinical trials. Control Clin Trials. 1989; 10: 110.
  • 26
    Fisher RA. On the interpretation of χ2 from contingency tables, and the calculation of P. J Royal Stat Soc. 1922; 85: 8794.
  • 27
    Kaplan EL,Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457481.
  • 28
    Giaccone G,O'Brien ME,Byrne MJ,Bard M,Kaukel E,Smit B. Phase II trial of ZD0473 as second-line therapy in mesothelioma. Eur J Cancer. 2002; 38 (suppl 8): S19S24.
  • 29
    Garland LL,Rankin C,Gandara DR, et al. Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study. J Clin Onco.l 2007; 25: 24062413.
  • 30
    Jahan TM,Gu L,Wang X, et al. Vatalanib for patients with previously untreated advanced malignant mesothelioma (MM): a phase II study by the Cancer and Leukemia Group B(CALGB 30, 107) [abstract]. Proc Am Soc Clin Oncol. 2006; 24 (18 suppl): 7081.
  • 31
    Karrison T,Kindler HL,Gandara DR, et al. Final analysis of a multi-center, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin (GC) plus bevacizumab (B) or placebo (P) in patients (pts) with malignant mesothelioma [abstract]. Proc Am Soc Clin Oncol. 2007; 25 (18 suppl): 7526.
  • 32
    Edwards JG,Abrams KR,Leverment JN,Spyt TJ,Waller DA,O'Byrne KJ. Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems. Thorax. 2000; 55: 731735.
  • 33
    Herndon JE,Green MR,Chahinian AP,Corson JM,Suzuki Y,Vogelzang NJ. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest. 1998; 113: 723731.